CG Oncology (CGON) Net Equity Issued and Repurchased (2024 - 2026)
CG Oncology's (CGON) quarterly Net Equity Issued and Repurchased came in at $391.5 million in Q1 2026, up 297.72% on a QoQ basis from $98.4 million in Q4 2025.
CG Oncology (CGON) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends
CG Oncology (CGON) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $391.5 million in Q1 2026.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $391.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $761.8 million (changed N/A YoY) and the FY2025 annual result came in at $147.4 million, down 33.91% from the prior year.
- Net Equity Issued and Repurchased grew to $391.5 million in Q1 2026, from $98.4 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $391.5 million in Q1 2026 to a low of $48.7 million in Q3 2025.
- A 3-year average of $190.4 million and a median of $160.8 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 55.87% in 2025, down 55.87% in 2025.
- Tracing CGON's Net Equity Issued and Repurchased over 3 years: stood at $223.1 million in 2024, then slumped by 55.87% to $98.4 million in 2025, then surged by 297.72% to $391.5 million in 2026.
- The last three Net Equity Issued and Repurchased figures came in at $391.5 million (Q1 2026), $98.4 million (Q4 2025), and $48.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 391.55 Mn |
| Mar 31, 2026 | 391.55 Mn |
| Dec 31, 2025 | 98.45 Mn |
| Dec 31, 2025 | 98.45 Mn |
| Sep 30, 2025 | 48.70 Mn |
| Sep 30, 2025 | 48.70 Mn |
| Dec 31, 2024 | 223.10 Mn |
| Dec 31, 2024 | 223.10 Mn |